Plus Other Stockholder Equity from 2010 to 2025

PSTV Stock  USD 0.73  0.05  7.35%   
Plus Therapeutics Other Stockholder Equity yearly trend continues to be fairly stable with very little volatility. Other Stockholder Equity will likely drop to about 286.3 M in 2025. During the period from 2010 to 2025, Plus Therapeutics Other Stockholder Equity regression line of quarterly data had mean square error of 6625.6 T and geometric mean of  343,322,602. View All Fundamentals
 
Other Stockholder Equity  
First Reported
2001-03-31
Previous Quarter
479.1 M
Current Value
484.4 M
Quarterly Volatility
153.9 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Plus Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Plus Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 337.7 K, Selling General Administrative of 10.2 M or Selling And Marketing Expenses of 637 K, as well as many indicators such as Price To Sales Ratio of 1.22, Dividend Yield of 0.0022 or Days Sales Outstanding of 46.47. Plus financial statements analysis is a perfect complement when working with Plus Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Plus Therapeutics Correlation against competitors.
For more information on how to buy Plus Stock please use our How to Invest in Plus Therapeutics guide.

Latest Plus Therapeutics' Other Stockholder Equity Growth Pattern

Below is the plot of the Other Stockholder Equity of Plus Therapeutics over the last few years. It is Plus Therapeutics' Other Stockholder Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Plus Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Other Stockholder Equity10 Years Trend
Slightly volatile
   Other Stockholder Equity   
       Timeline  

Plus Other Stockholder Equity Regression Statistics

Arithmetic Mean371,841,662
Geometric Mean343,322,602
Coefficient Of Variation31.02
Mean Deviation87,291,030
Median413,304,000
Standard Deviation115,356,165
Sample Variance13307T
Range486M
R-Value0.73
Mean Square Error6625.6T
R-Squared0.54
Significance0
Slope17,727,289
Total Sum of Squares199605.7T

Plus Other Stockholder Equity History

2025286.3 M
2024551 M
2023479.1 M
2022473.6 M
2021457.7 M
2020436.5 M
2019426.4 M

About Plus Therapeutics Financial Statements

Plus Therapeutics investors use historical fundamental indicators, such as Plus Therapeutics' Other Stockholder Equity, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Plus Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Other Stockholder Equity551 M286.3 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Plus Stock Analysis

When running Plus Therapeutics' price analysis, check to measure Plus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Plus Therapeutics is operating at the current time. Most of Plus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Plus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Plus Therapeutics' price. Additionally, you may evaluate how the addition of Plus Therapeutics to your portfolios can decrease your overall portfolio volatility.